Health Care
Pfenex shares shoot up on getting FDA approval for its osteoporosis drug
Shares of Pfenex (NYSE: PFNX) jumped over 15% in today's pre-market trading session as the clinical-stage biotech company received approval…
Strong pipeline and innovation make Novartis a sure bet, despite setbacks
The uncertainties surrounding drug development and intense competition are the primary challenges facing pharmaceutical companies, which also prompt investors to…
Ovid Therapeutics stock gains on positive epilepsy trial data
Ovid Therapeutics Inc. (NASDAQ: OVID) stock climbed to an 8-month high of $3.05 on Tuesday after positive initial data from…
Wall St expecting a turn-around quarter from Rite Aid in Q2
Things haven’t been working out so well for Rite Aid (NYSE: RAD) since the past three years. The company’s inability…
Will Zynerba Zygel trial be extended amid safety warning?
Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock retreated on Wednesday after serious adverse events in phase 2 clinical trial of transdermal cannabidiol…
Three companies that are haunted by multiple lawsuits
Several companies have battled lawsuits from time to time for various reasons. However, sometimes companies face thousands of lawsuits for…
Alexion Pharmaceuticals could still be a valuable addition to your portfolio
Biopharmaceutical firm Alexion Pharmaceuticals (NASDAQ: ALXN) has been going through a volatile phase lately. The company was expected to be…
Lundbeck to acquire Alder BioPharmaceuticals for $1.95 billion; Alder stock hits new 52-week high
Denmark-based biopharma company Lundbeck announced today that it will acquire Alder BioPharmaceuticals (NASDAQ: ALDR) for $1.95 billion. Alder stock, which…
Will Allergan-AbbVie merger be intercepted
Allergan plc (NYSE: AGN) continued to dominate in the tissue expander market as the demand for plastic surgeries is increasing…
Catalyst Pharmaceuticals stock soars to record high
Catalyst Pharmaceuticals (NASDAQ: CPRX) stock soared to a record high of $7.67 on Wednesday as phase 3 trial results date…
Novartis scores another point in multiple sclerosis therapy, stock rises
Swiss pharmaceutical giant Novartis International AG (NYSE: NVS) on Friday said its ofatumumab met the primary and secondary endpoints of…
Johnson & Johnson tumbles on rating downgrade, after opioid ruling
Johnson & Johnson (NYSE: JNJ) continued the slide Wednesday after suffering a big loss in the previous trading session as…
4 biotech stocks that are ideal takeover targets
Speculation plays a big role when investing in biotech stocks, hence making them highly volatile. It could be after years…
Lannett stock jumps more than 15% after topping Q4 earnings and revenue estimates
Generic drug manufacturer Lannett's (NYSE: LCI) stock surged more than 15% after it reported Q4 earnings results. The company's bottom…
Veeva Systems Q2 profit beats estimates, CFO Tim Cabral to retire
Veeva Systems Inc. (NYSE: VEEV) reported a 58% jump in earnings for the second quarter of 2020 as higher subscription…
Why Arbutus Biopharma stock dipped to 11-year low?
Arbutus Biopharma Corporation (NASDAQ: ABUS) stock plunged to an 11-year low of $1.31 on Monday due to considerable downside risk…
Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan
Bristol-Myers-Squibb (NASDAQ: BMY) announced that Amgen (NASDAQ: AMGN) will acquire Celgene's (NASDAQ: CELG) Otezla business for $13.4 billion in a…